Swiss Hormone Manufacturers: GLP-1 Era (2026)

Switzerland is one of the world’s most concentrated hubs for hormone, peptide hormone, and steroid manufacturing. According to World Bank WITS comtrade data, Swiss exports of other hormones and derivatives under HS 293799 reached $971.2 million in 2024, anchored by Bachem in peptide hormones, Sandoz in corticosteroid generics, and Helsinn in endocrine supportive care. The GLP-1 wave is reshaping the entire segment, but most Swiss hormone manufacturers still chase global buyers through trade fairs and field reps that grow more expensive every year.

Switzerland’s Position in Global Hormone Manufacturing

The Swiss hormone segment sits inside a much larger pharma engine. Total Swiss chemical and pharmaceutical exports reached a record CHF 152.1 billion in 2025, with pharmaceuticals representing 77.8% of that value, according to scienceindustries. The pharmaceutical industry directly employs 50,600 people in Switzerland and contributes 5.8% of GDP, per Interpharma.

Within that engine, the hormone, peptide hormone, and steroid sub-category covered by HS 2937 punches well above its weight. The category captures three distinct manufacturer types operating in Switzerland today:

• Peptide hormone CDMOs producing GLP-1 analogues like semaglutide and liraglutide, growth-hormone analogues, GnRH agonists, and oxytocin analogues
• Corticosteroid and adrenal-hormone generics producers supplying global pharmacies with dexamethasone, prednisolone, and hydrocortisone
• Endocrine and oncology supportive-care specialists developing branded hormone-modulating therapies

Each of these manufacturer types serves a different buyer profile. Each one is under acute pressure to build pipeline at scale as the GLP-1 boom reorders the entire peptide-API market.

The GLP-1 Wave Is Rewriting Swiss Peptide Manufacturing

The single most important shift in Swiss hormone manufacturing is the rise of GLP-1 receptor agonists, the class of peptide hormones behind Ozempic, Wegovy, Mounjaro, and Zepbound. The global GLP-1 drugs market hit $52.95 billion in 2025 and is forecast to reach $58.05 billion in 2026, climbing to $132.79 billion by 2035 at a 9.63% CAGR.

Bachem, headquartered in Bubendorf near Basel, is the world’s largest publicly traded peptide CDMO and one of the most exposed companies to this wave. In November 2025, Switzerland Global Enterprise reported that Bachem secured a follow-up peptide supply contract worth a minimum of CHF 1 billion over five years (2025-2029).

Thomas Meier, CEO of Bachem, framed the deal this way:

“We are very pleased about this follow-up order and the renewed confidence in our work. Long-term collaborations are important for us and our partners: they enable us to reliably plan the development and utilization of production capacities.”

To meet GLP-1 driven demand, Bachem has announced major capacity expansions across its network. According to Manufacturing Chemist (May 2025), the company is investing in:

• Bubendorf (Switzerland): Building K, a new large-scale peptide production facility
• Sisslerfeld (Switzerland): A new northwestern Switzerland site in concept design, described in Bachem’s own publication as “one of the most ambitious industrial expansions in Switzerland”
• Vista (California): Capacity scaling to approach one metric tonne of annual peptide output
• St Helens (UK): Diagnostic peptide output doubled

The same pressure that drove Bachem’s expansion is now creating a 2026 inflection point. Novo Nordisk’s semaglutide patent expires in several countries including India and China in 2026, according to Chemical & Engineering News. That will trigger a wave of generic semaglutide programs needing high-purity peptide APIs and CDMO capacity.

Steroid and Corticosteroid Manufacturing in Switzerland

The steroid manufacturing side of HS 2937 is anchored by Sandoz Group, headquartered in Basel. Sandoz reported full-year 2025 sales of approximately $11.1 billion, with biosimilars contributing roughly 30% and generics the remainder. The company’s generics portfolio includes long-running corticosteroid franchises (dexamethasone, prednisolone, hydrocortisone derivatives) supplied to hospital and retail channels globally.

Beyond Sandoz, Switzerland hosts a network of specialty steroid intermediates suppliers, contract synthesis houses, and analytical laboratories. These mid-sized players serve generic-drug manufacturers in India, Brazil, the United States, and Europe. The customer is rarely a single buyer. It is a procurement committee that includes API sourcing, regulatory affairs, quality, and supply-chain leads.

Helsinn and Endocrine Supportive Care

The third pillar of the Swiss hormone segment is Helsinn Group, headquartered in Lugano. Helsinn focuses on cancer supportive care, oncology, and dermato-oncology. Its hormone-adjacent franchise includes endocrine-mediated antiemetics like AKYNZEO (netupitant-palonosetron) and ALOXI (palonosetron) for chemotherapy-induced nausea and vomiting.

In January 2025, Helsinn announced a renewed Distribution and Licence Agreement with ESTEVE for the German market. Helsinn maintains direct commercial operations in the United States, manufacturing in Ireland, and a partner network across more than 90 countries.

Helsinn-style branded specialty pharma companies, common across the Lugano and Lausanne corridors, sell to a different audience: hospital pharmacy committees, oncology key opinion leaders, payers, and regional distributors. The buying journey is long, technical, and relationship-heavy.

Why Traditional Sales Channels Are Failing Swiss Hormone Manufacturers

Across all three manufacturer types, Swiss hormone companies still rely on the same handful of channels their predecessors used twenty years ago. Each one is showing diminishing returns.

Trade fairs (CPhI Worldwide, BIO-Europe, DCAT Week, ACHEMA): CPhI Worldwide 2025 in Frankfurt drew 2,400 exhibiting firms and 67,000 visitors. The Swiss Pavilion organized by S-GE is consistently full. The math against a hormone CDMO: a booth runs $15,000 to $50,000+ before travel and staffing, you meet whoever walks past, and the people who actually drive supplier selection (CMC leads, quality directors, regulatory affairs) rarely roam the floor. Cost per qualified lead: $300 to $900+.

Scientific advisor and KOL networks: Endocrinology and oncology KOL networks still open doors at academic medical centers and large pharma R&D groups. The channel works but does not scale. Each KOL relationship covers a narrow therapeutic area, requires months to cultivate, and cannot be cloned across 200 target accounts.

Distributor and licensing networks: Many Swiss specialty hormone manufacturers reach foreign markets through licensees. The licensee owns the customer relationship. When they switch to a lower-cost API or a competing brand, the Swiss principal has no visibility and limited leverage at renewal.

Field sales representatives: A pharma-experienced rep covering a single European market costs $100,000 to $150,000 per year fully loaded, before generating one qualified opportunity. Covering five markets requires five reps with different languages and regulatory backgrounds. Cost per qualified lead: $500 to $1,200+.

Cold calling across borders: To penetrate a buying committee inside a single generic-drug company you need to reach API sourcing, R&D, QA, regulatory affairs, and plant operations. That is 20+ dial attempts per account in the buyer’s native language with deep technical credibility. Finding native German, French, Italian, Mandarin, Hindi, and Portuguese speakers who can also discuss DMF filings, ICH stability data, and GMP audits is nearly impossible to staff for in-house.

Trade missions: S-GE delegations and Swiss embassy export programs produce a handful of warm introductions per trip, not a sustained pipeline.

The structural problem with all of these channels is the same: they reach one person at a time in a sector where supplier selection involves five to eleven stakeholders, per Gartner B2B buying-group research.

A Tighter Trade Environment Raises the Stakes

The current trade environment makes sales efficiency non-optional. As Interpharma CEO Rene Buholzer told Pharma Boardroom in 2025, recent US tariffs on Swiss goods and shifting global trade dynamics represent a “wake-up call” that has produced what he described as a “smaller world for trade.” Swiss hormone manufacturers cannot afford to lose a quarter waiting for buyers to appear at the next trade fair.

How AI-Powered Outbound Solves the Hormone-Sector Pipeline Problem

Traditional outbound fails for hormone, peptide, and steroid manufacturers because it treats highly technical, multi-stakeholder, regulator-heavy sales like simple lead-gen. AI-powered outbound works fundamentally differently.

Buying-Committee Coverage Instead of Single-Threaded Outreach

A generic semaglutide buyer makes a multi-stakeholder decision: API sourcing leads care about pricing and supply reliability, R&D directors want analytical method packages and impurity profiles, QA heads want GMP and audit history, regulatory affairs leads want DMF and CEP documentation, and plant managers want delivery cadence. AI outbound identifies and engages all of those stakeholders in parallel with messaging tuned to each role.

Signal Detection Synced to the Hormone Buying Cycle

AI outbound watches for the specific signals that indicate a hormone manufacturer is ready to talk to a new supplier:

• GLP-1 patent expiries in target jurisdictions (generics manufacturers need API partners)
• New ANDA filings or biosimilar submissions in hormone categories
• Facility expansions and capacity announcements by generic-drug and specialty-pharma companies
• Leadership changes in CMC, procurement, or supply-chain roles
• Tender publications by national health systems for corticosteroid and hormone supply

When a signal fires, outreach lands within days, not at the next CPhI in October.

Technical Personalization at Scale

Hormone buyers need extensive documentation: DMFs, CEPs, GMP certificates, ICH stability data, impurity profiles, regulatory correspondence with Swissmedic, FDA, EMA. AI outbound attaches the right packet to the right person on the right day. A QA director gets your audit history. A regulatory lead gets your DMF and CEP references. A CMC scientist gets your analytical method packages and process descriptions. The Swiss reputation for precision and quality is communicated in the buyer’s own language, framed against their own specifications.

What This Looks Like in Practice

Consider a mid-sized Swiss peptide CDMO based in the Basel cluster, specializing in GLP-1 analogues and growth-hormone peptides. Today they attend CPhI, BIO-Europe, and Swiss Biotech Day annually, work with two licensees, and rely on a small scientific-advisor network. They have very limited visibility into which end customers actually use their APIs.

With an AI-powered growth engine:

1. The system maps 300+ generic-drug, biosimilar, and biotech companies globally that need GLP-1 or growth-hormone peptide-API capacity
2. Buying committees are built for each account: API sourcing, CMC, QA, regulatory, procurement
3. Personalized outreach reaches each stakeholder with role-specific technical content in their native language
4. Signal detection flags a generic manufacturer that just filed an ANDA for liraglutide
5. A focused multi-stakeholder campaign reaches that company within the same week
6. Direct relationships are built that reduce licensee dependency at renewal

Cost per qualified lead with AI outbound: $150 to $300, dropping as the system learns which sub-segments, role combinations, and signal types convert. Trade fairs cost $300 to $900+ per lead and scale linearly. Field reps cost $500 to $1,200+ per lead and scale worse than linearly. The AI engine compounds. The second 1,000 prospects cost less to reach than the first 1,000, and the third 1,000 less than the second.

The Structural Advantage for Swiss Hormone Manufacturers

The Swiss hormone segment has a unique edge: regulatory complexity creates information asymmetry. Companies that can clearly communicate Swissmedic certifications, EMA and FDA inspection histories, GMP compliance, DMF and CEP holdings, and technical depth to the right roles at the right time win contracts. Those that wait for buyers to find them at CPhI lose to suppliers who already showed up in the inbox.

Demand for Swiss hormone products is strong. Quality reputation is built. Patent expiries, biosimilar pipelines, and the GLP-1 generics wave are creating more buyers, not fewer. The bottleneck is not manufacturing capability. The bottleneck is reaching the right buyers efficiently at scale, in their native language, at the moment they are ready to switch.

AI outbound does not replace your scientific or regulatory teams. It amplifies them by making sure every buying committee that matters sees your capabilities at the right moment.

Getting Started

Swiss hormone manufacturers do not need to rebuild sales from zero. The practical path:

1. Define your Ideal Customer Profile (ICP): Which therapeutic areas, company sizes, and geographies represent your highest-value opportunities? Generic peptide manufacturers in India? Specialty-pharma in the EU? Hospital tender programs in the Gulf?
2. Map buying committees: For your top 50 target accounts, identify every relevant decision-maker across API sourcing, CMC, QA, regulatory, and procurement
3. Prepare technical content: Organize DMFs, CEPs, GMP certificates, stability data, audit summaries, and capability decks for digital delivery
4. Launch multi-threaded campaigns: Engage complete buying committees, not single procurement contacts
5. Measure and iterate: Track response rates by role, therapeutic area, geography, and signal type

We build AI-powered growth engines specifically for B2B manufacturers. See how it works, explore our case studies, or read related coverage on the Swiss pharma and biotech export landscape and Switzerland’s broader manufacturing export base.

Frequently Asked Questions

How big is Switzerland’s hormone and steroid export market?

Swiss exports of other hormones and derivatives under HS code 293799 reached approximately $971.2 million in 2024, according to World Bank WITS comtrade data. That figure sits inside a much larger Swiss pharmaceutical export base of more than CHF 118 billion in 2025, with hormone-related products growing fastest due to GLP-1 demand.

Who are the largest Swiss hormone manufacturers?

The three most visible players are Bachem (Bubendorf, the largest publicly traded peptide CDMO globally, leading on GLP-1 analogues), Sandoz (Basel, corticosteroid and hormone generics), and Helsinn Group (Lugano, endocrine and oncology supportive care). Around these anchors sits a network of mid-sized peptide CDMOs, steroid intermediates suppliers, and specialty endocrine companies.

How is the GLP-1 boom changing Swiss peptide manufacturing?

The global GLP-1 drugs market is projected to grow from $52.95 billion in 2025 to $132.79 billion by 2035. With semaglutide patents expiring in 2026 in markets like India and China, generic manufacturers worldwide need high-purity peptide APIs. Bachem has secured a CHF 1 billion five-year peptide supply contract and is investing in multiple Swiss and US sites to meet demand.

Can AI outbound work for highly regulated hormone API sales?

Yes. AI outbound handles prospecting, buying-committee mapping, and initial multi-threaded engagement. All regulatory claims, technical documentation, and stability data are prepared by your team and delivered through the system. The AI personalizes which packet reaches which stakeholder. It does not generate regulatory claims or modify technical files.

What results should a Swiss hormone manufacturer expect?

Most peptide and specialty-pharma campaigns generate qualified responses within four to six weeks. Given hormone-API sales cycles of six to eighteen months for supplier qualification, first contracts typically close within six to twelve months. The advantage is a consistent pipeline rather than the once-a-year spike that follows a trade fair.

---

Ready to build a hormone-API or peptide-CDMO pipeline that does not depend on CPhI? Get in touch to discuss how AI-powered outbound can transform your commercial engine.